Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0227 | 1 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.0227 | 1 | 0.5 |
Echinococcus granulosus | Glycosyl transferase family 35 | 0.0227 | 1 | 0.5 |
Mycobacterium ulcerans | glycogen phosphorylase GlgP | 0.0098 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable glycogen phosphorylase GlgP | 0.0098 | 0 | 0.5 |
Schistosoma mansoni | glycogen phosphorylase | 0.0227 | 1 | 1 |
Chlamydia trachomatis | glycogen phosphorylase | 0.0227 | 1 | 0.5 |
Trichomonas vaginalis | glycogen phosphorylase, putative | 0.0227 | 1 | 0.5 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0227 | 1 | 1 |
Loa Loa (eye worm) | glycogen phosphorylase | 0.0227 | 1 | 1 |
Entamoeba histolytica | glycogen phosphorylase, putative | 0.0227 | 1 | 1 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0227 | 1 | 0.5 |
Echinococcus granulosus | glycogen phosphorylase | 0.0227 | 1 | 0.5 |
Echinococcus multilocularis | Glycosyl transferase, family 35 | 0.0227 | 1 | 0.5 |
Giardia lamblia | Glycogen phosphorylase | 0.0227 | 1 | 0.5 |
Onchocerca volvulus | Glycogen phosphorylase homolog | 0.0227 | 1 | 1 |
Echinococcus multilocularis | glycogen phosphorylase | 0.0227 | 1 | 0.5 |
Schistosoma mansoni | glycogen phosphorylase | 0.0227 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.8913 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS for Inhibitors of Vif-A3G Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | ||
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.